JSH receives consulting fees for 4D Molecular Therapeutics, Abpro, Adverum, AffaMed Therapeutics, Applied Genetics Technologies Corporation, Akouos, Allegro, Annexon, Apellis, AsclepiX Therapeutics, Bausch + Lomb, Biovisics, Clearside, Curacle, DTx Pharma, Exegenesis, Roche and Genentech, Glaukos, Gyroscope Therapeutics, ImmunoGen, Iveric Bio, Janssen R&D, jCyte, Kriya, Nanoscope, NGM Bio, Notal Vision, Novartis, Ocular Therapeutix, Ocuphire, OcuTerra, OliX, ONL Therapeutics, Outlook Therapeutics, Palatin Technologies, Perceive Biotherapeutics, Ray Therapeutics, Regeneron Pharmaceuticals, REGENXBIO, RetinAI, RevOpsis Therapeutics, Stealth BioTherapeutics, Théa Pharmaceuticals, and Vanotech; receives grants or contracts for 4D Molecular Technologies, Annexon, Apellis, AsclepiX Therapeutics, Ashvattha, Bayer, Cognition Therapeutics, Curacle, Roche and Genentech, Gyroscope Therapeutics, Iveric Bio, Janssen R&D, Kodiak, NGM, Notal Vision, Novartis, OcuTerra, Perceive Bio, Regeneron Pharmaceuticals, and REGENXBIO; has equity in Adverum, Aldeyra Therapeutics, Allegro, Aviceda, DTx Pharma, jCyte, Ocuphire, Ocular Therapeutix, RevOpsis Therapeutics, Vinci Pharmaceuticals, and Vitranu; and is on the Board of Directors for Ocular Therapeutix. XZ and SL are employees of and hold stock/stock options in Bayer AG. KR was an employee of Regeneron Pharmaceuticals, Inc. at the time of the study and is a stockholder of Regeneron Pharmaceuticals, Inc. AJB is an employee of and holds stock/stock options in Regeneron Pharmaceuticals, Inc.